“P100 | ATOGEPANT DEMONSTRATES GREATER IMPROVEMENT IN FUNCTION USING THE ACTIVITY IMPAIRMENT IN MIGRAINE-DIARY (AIM-D) DURING INTERICTAL DAYS: POST-HOC ANALYSIS FROM THE PROGRESS CHRONIC MIGRAINE TRIAL: R. Masselli1, R. B. Lipton2, P. Gandhi3, A. Maassen van den Brink4, E. Leroux5, R. Halker Singh6, M. Duan3, B. Dabruzzo3, K. Umashankar3, J. Stokes3, D. C. Buse7 | 1AbbVie Srl, Rome, Italy; 2Department of Neurology, General Hospital Sint-Jan Bruges, Belgium; 3AbbVie Inc. North Chicago, IL, USA; 4Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; 5Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain; Headache and Neurological Pain Research; 6Headache and Neurological Pain Research Group, Vall d’Hebron Institute of Research, Universitat Autonoma de Barcelona, Spain; 7University Hospital Bonn, Germany; 8Charité Universitätsmedizin Berlin, Germany; 9Neurology Department, Hospital da Luz, Lisboa, Portugal; 10Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Lisboa, Portugal” (2026) Confinia Cephalalgica, 36(s1). doi:10.4081/cc.2026.16056.